Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors--new prospects for treatment of hyperparathyroidism with vitamin d
(2002) In The Journal of clinical endocrinology and metabolism 87(12). p.9-5826- Abstract
Vitamin D analogues are in clinical use for prevention and treatment of secondary hyperparathyroidism (HPT) in chronic renal failure. Despite recent advances there is a need for vitamin D derivatives with maintained parathyroid hormone suppressive activity and less hypercalcemic and hyperphosphatemic toxicity. Here we show coincident increased expression of the vitamin D activating enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) and reduced expressions of the 1,25(OH)(2)D(3) catabolizing enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) in the majority of investigated parathyroid adenomas and secondary hyperplastic glands. In addition, this relationship was found for the mitochondrial CYP27A... (More)
Vitamin D analogues are in clinical use for prevention and treatment of secondary hyperparathyroidism (HPT) in chronic renal failure. Despite recent advances there is a need for vitamin D derivatives with maintained parathyroid hormone suppressive activity and less hypercalcemic and hyperphosphatemic toxicity. Here we show coincident increased expression of the vitamin D activating enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) and reduced expressions of the 1,25(OH)(2)D(3) catabolizing enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) in the majority of investigated parathyroid adenomas and secondary hyperplastic glands. In addition, this relationship was found for the mitochondrial CYP27A enzyme (25-hydroxylase), a potential physiological vitamin D(3) 25-hydroxylase. These findings should be considered in future development of vitamin D analogues for treatment of HPT.
(Less)
- author
- Correa, Pamela LU ; Segersten, Ulrika ; Hellman, Per ; Åkerström, Göran and Westin, Gunnar
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism, Adenoma/metabolism, Carcinoma/metabolism, Humans, Hyperparathyroidism/drug therapy, Hyperplasia, Parathyroid Diseases/metabolism, Parathyroid Glands/pathology, Parathyroid Neoplasms/metabolism, Vitamin D/analogs & derivatives
- in
- The Journal of clinical endocrinology and metabolism
- volume
- 87
- issue
- 12
- pages
- 9 - 5826
- publisher
- Oxford University Press
- external identifiers
-
- pmid:12466393
- scopus:0036920846
- ISSN
- 0021-972X
- DOI
- 10.1210/jc.2002-021356
- language
- English
- LU publication?
- no
- id
- 92e7476b-8caa-47af-9c83-c7f631374237
- date added to LUP
- 2021-11-10 15:44:03
- date last changed
- 2024-06-01 20:25:39
@article{92e7476b-8caa-47af-9c83-c7f631374237,
abstract = {{<p>Vitamin D analogues are in clinical use for prevention and treatment of secondary hyperparathyroidism (HPT) in chronic renal failure. Despite recent advances there is a need for vitamin D derivatives with maintained parathyroid hormone suppressive activity and less hypercalcemic and hyperphosphatemic toxicity. Here we show coincident increased expression of the vitamin D activating enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) and reduced expressions of the 1,25(OH)(2)D(3) catabolizing enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) in the majority of investigated parathyroid adenomas and secondary hyperplastic glands. In addition, this relationship was found for the mitochondrial CYP27A enzyme (25-hydroxylase), a potential physiological vitamin D(3) 25-hydroxylase. These findings should be considered in future development of vitamin D analogues for treatment of HPT.</p>}},
author = {{Correa, Pamela and Segersten, Ulrika and Hellman, Per and Åkerström, Göran and Westin, Gunnar}},
issn = {{0021-972X}},
keywords = {{25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism; Adenoma/metabolism; Carcinoma/metabolism; Humans; Hyperparathyroidism/drug therapy; Hyperplasia; Parathyroid Diseases/metabolism; Parathyroid Glands/pathology; Parathyroid Neoplasms/metabolism; Vitamin D/analogs & derivatives}},
language = {{eng}},
number = {{12}},
pages = {{9--5826}},
publisher = {{Oxford University Press}},
series = {{The Journal of clinical endocrinology and metabolism}},
title = {{Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors--new prospects for treatment of hyperparathyroidism with vitamin d}},
url = {{http://dx.doi.org/10.1210/jc.2002-021356}},
doi = {{10.1210/jc.2002-021356}},
volume = {{87}},
year = {{2002}},
}